Left Ventricular Dysfunction and Chemotherapeutic Agents
- 8 March 2018
- journal article
- review article
- Published by Springer Nature in Current Cardiology Reports
- Vol. 20 (4) , 20
Abstract
We aim to summarize the effect of cancer therapy-related cardiotoxicity on the development of left ventricular (LV) dysfunction.Keywords
This publication has 43 references indexed in Scilit:
- The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma PatientsJACC: Heart Failure, 2013
- Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice GuidelinesAnnals of Oncology, 2012
- Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological PreventionJNCI: Journal of the National Cancer Institute, 2010
- Anthracycline-Induced CardiomyopathyJACC, 2010
- American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late EffectsJournal of Clinical Oncology, 2007
- Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme InhibitionCirculation, 2006
- Cardiovascular Complications of Cancer TherapyCirculation, 2004
- Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose ChemotherapyCirculation, 2004
- Minor Increases in Plasma Troponin I Predict Decreased Left Ventricular Ejection Fraction after High-Dose ChemotherapyClinical Chemistry, 2003
- Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapyJACC, 2000